Have a feature idea you'd love to see implemented?
Let us know!
COLL Collegium Pharmaceutical Inc
Price (delayed)
$33.18
Market cap
$1.07B
P/E Ratio
12.24
Dividend/share
N/A
EPS
$2.71
Enterprise value
$1.88B
Collegium Pharmaceutical Inc. is a specialty pharmaceutical company committed to being the leader in responsible pain management. Collegium's headquarters are located in Stoughton, Massachusetts.
Highlights
Collegium Pharmaceutical's gross profit has increased by 33% YoY and by 4.6% QoQ
The equity is up by 31% year-on-year and by 8% since the previous quarter
COLL's debt has surged by 56% since the previous quarter and by 22% year-on-year
The quick ratio has declined by 22% year-on-year and by 17% since the previous quarter
Key stats
What are the main financial stats of COLL
Market
Valuations
Earnings
Shares outstanding
32.25M
Market cap
$1.07B
Enterprise value
$1.88B
Price to earnings (P/E)
12.24
Price to book (P/B)
4.56
Price to sales (P/S)
1.79
EV/EBIT
9.46
EV/EBITDA
5.4
EV/Sales
3.14
Revenue
$599.25M
Gross profit
$373.69M
Net income
$88.59M
EBIT
$198.61M
EBITDA
$348.13M
Free cash flow
$192.43M
Per share
Balance sheet
Liquidity
EPS
$2.71
EPS diluted
$2.33
Free cash flow per share
$5.97
Book value per share
$7.27
Revenue per share
$18.58
TBVPS
$16.81
Total assets
$1.64B
Total liabilities
$1.4B
Debt
$874.4M
Equity
$234.28M
Working capital
-$15.62M
Debt to equity
3.73
Current ratio
0.97
Quick ratio
0.82
Net debt/EBITDA
2.32
Margins
Efficiency
Dividend
EBITDA margin
58.1%
Gross margin
62.4%
Net margin
14.8%
Operating margin
32.3%
Return on assets
7.2%
Return on equity
40.8%
Return on invested capital
31.9%
Return on capital employed
16.9%
Return on sales
33.1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
COLL stock price
How has the Collegium Pharmaceutical stock price performed over time
Intraday
-1.81%
1 week
13.86%
1 month
10.27%
1 year
2.06%
YTD
15.81%
QTD
15.81%
Financial performance
How have Collegium Pharmaceutical's revenue and profit performed over time
Revenue
$599.25M
Gross profit
$373.69M
Operating income
$193.47M
Net income
$88.59M
Gross margin
62.4%
Net margin
14.8%
Collegium Pharmaceutical's operating income has surged by 65% YoY but it has decreased by 5% QoQ
Collegium Pharmaceutical's operating margin has surged by 51% YoY but it has decreased by 8% QoQ
Collegium Pharmaceutical's gross profit has increased by 33% YoY and by 4.6% QoQ
The gross margin rose by 21% year-on-year
Growth
What is Collegium Pharmaceutical's growth rate over time
Valuation
What is Collegium Pharmaceutical stock price valuation
P/E
12.24
P/B
4.56
P/S
1.79
EV/EBIT
9.46
EV/EBITDA
5.4
EV/Sales
3.14
COLL's P/E is 19% below its last 4 quarters average of 15.1
Collegium Pharmaceutical's EPS has decreased by 11% from the previous quarter
The equity is up by 31% year-on-year and by 8% since the previous quarter
The price to book (P/B) is 14% higher than the 5-year quarterly average of 4.0 but 12% lower than the last 4 quarters average of 5.2
COLL's price to sales (P/S) is 11% lower than its 5-year quarterly average of 2.0 and 11% lower than its last 4 quarters average of 2.0
The revenue is up by 10% year-on-year and by 3.9% since the previous quarter
Efficiency
How efficient is Collegium Pharmaceutical business performance
The ROIC has soared by 85% YoY but it has contracted by 19% from the previous quarter
Collegium Pharmaceutical's ROS has soared by 71% YoY but it has decreased by 11% from the previous quarter
The company's return on assets fell by 19% QoQ
The ROE is down by 17% QoQ
Dividends
What is COLL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for COLL.
Financial health
How did Collegium Pharmaceutical financials performed over time
Collegium Pharmaceutical's total assets is 17% more than its total liabilities
Collegium Pharmaceutical's total liabilities has surged by 67% QoQ and by 40% YoY
Collegium Pharmaceutical's total assets has soared by 55% from the previous quarter and by 39% YoY
COLL's debt has surged by 56% since the previous quarter and by 22% year-on-year
The debt to equity rose by 45% QoQ but it fell by 7% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.